Exploring Terbium-161 PSMA Therapy for Advanced Prostate Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This first-in-Taiwan trial uses a dose-escalation design to evaluate safety, dosimetry, biodistribution, pharmacokinetics, and preliminary efficacy of 161Tb-PSMA-I&T in metastatic castration-resistant prostate cancer. The radioligand therapy targets PSMA with terbium-161, which may offer enhanced tumor kill in small or poorly perfused lesions compared with conventional beta emitters. The study builds on prior 161Tb-PSMA-I&T data and aims to inform future clinical development. Participants have progressed on standard therapies and meet criteria including prior taxane and AR pathway inhibitor exposure. The trial is conducted at National Taiwan University Hospital and NTU Cancer Center.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥ 20 years, ability to understand and willingness to sign informed consent, cooperate with all study-related procedures and assessments including blood tests and imaging
2. Histologically confirmed adenocarcinoma of the prostate with evidence of metastatic castration-resistant prostate cancer (mCRPC)
3. Prior surgical orchiectomy or chemical castration maintained on luteinizing hormone-releasing hormone analog, with a serum testosterone level \<50 ng/dL (castrate range)
4. Prior treated with at least one line of taxane-based chemotherapy unless medically unsuitable, and at least one line of androgen receptor pathway inhibitor (e.g., abiraterone, enzalutamide, apalutamide, or darolutamide)
5. Prior treated with 177Lu-labeled PSMA RLT unless medically unsuitable or declined by the patient
6. Progressive disease defined according to Prostate Cancer Clinical Trials Working Group 3: Either a PSA progression of more than 2 rising PSA values from baseline with intervals ≥ 1 week, or a soft-tissue progression on images per RECIST 1.1 criteria, or a bone progression on images with more than 2 new lesions
7. Evidence of significant PSMA-avid lesions on 68Ga- or 18F-labeled PSMA PET/CT within 12 weeks prior to screening, which defined as 68Ga-PSMA or 18F-PSMA uptake greater than that of liver or spleen parenchyma (depend on the tracer used) in at least one metastatic lesion of any size in any organ system
8. A life expectancy of ≥ 6 months and Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
9. Adequate bone marrow and organ functions 9.1 Hemoglobin ≥ 10 g/dL without RBC transfusion within 4 weeks 9.2 Absolute neutrophil count ≥ 1.5 × 109/L 9.3 Platelet count ≥ 150 × 109/L 9.4 Creatinine clearance ≥ 50 mL/min (Cockcroft-Gault) 9.5 AST and ALT ≤ 3 × ULN, total bilirubin ≤ 1.5 × ULN
10. Willingness to comply with the use of medically acceptable forms of barrier contraception if sexually active

Exclusion Criteria:

1. History of allergic reaction to PSMA-targeted compounds or radiometals
2. Prior radioligand therapy with 223Ra or 177Lu-PSMA within 6 months
3. Prior surgery or radiotherapy within 4 weeks prior to first investigational dose
4. Prior systemic therapies against prostate cancer within 4 weeks, including androgen receptor pathway inhibitor, chemotherapy, targeted therapy such as PARP inhibitors (PARPi)
5. Discordant disease on PET images: FDG-positive disease with minimal PSMA expression
6. Urinary tract obstruction causing hydronephrosis unless appropriately treated beforehand
7. Known symptomatic brain metastases or leptomeningeal disease, symptomatic or impending cord compression unless appropriately treated beforehand
8. Other active malignancy requiring systemic treatment
9. Significant cardiovascular disease (e.g., recent myocardial infarction, unstable angina)
10. Concurrent severe uncontrolled illness that may jeopardize patient safety, including uncontrolled infections

Where it's running

• National Taiwan University Cancer Center
  Taipei, Taiwan Recruiting
• National Taiwan University Hospital
  Taipei, Taiwan Recruiting

Study contacts

• Principal investigator: Ching-Chu Lu — National Taiwan University Hospital
• Study coordinator: Pei-Ju Chuang
• Email: pjchuang.ntucc@gmail.com
• Phone: +886-2-2322-0322

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• GI-102 with Pasritamig for metastatic prostate cancer

  This trial tests GI-102 together with Pasritamig to see if it is safe and may help men whose metastatic castration-resistant prostate cancer has progressed after prior hormonal therapy.

  Recruiting at 5 sites Phase 1/2 GI Innovation, Inc. · New York, New York and 5 other locations · NCT07871435

• REGN15505 Alone or With Cemiplimab or REGN4336 in Advanced Prostate Cancer and Kidney Cancer

  This trial tests REGN15505 by itself or with cemiplimab or REGN4336 to see if it helps adults with metastatic castration-resistant prostate cancer or clear cell renal cell carcinoma.

  Recruiting at 6 sites Phase 1/2 Regeneron Pharmaceuticals · Goodyear, Arizona and 5 other locations · NCT07594106

• Oral INR731 alone or with androgen receptor blockers for metastatic castration-resistant prostate cancer

  This tests whether oral INR731 by itself or with androgen receptor pathway inhibitors is safe, tolerable, and shows early anti‑tumor activity in adults with metastatic castration‑resistant prostate cancer.

  Recruiting at 13 sites Phase 1 Novartis · Boston, Massachusetts and 12 other locations · NCT07570979

• Cannabidiol for Pain Relief in End-Stage Metastatic Castration-Resistant Prostate Cancer

  This study tests whether cannabidiol (CBD) can reduce opioid use and relieve pain in men with end-stage metastatic castration-resistant prostate cancer.

  Recruiting Phase 2 Regionshospital Nordjylland · Gistrup · NCT07549256

• Lu‑177 PSMA‑3D1015 injections for men with metastatic castration‑resistant prostate cancer

  This trial will test Lu‑177 PSMA‑3D1015 injections in adult men with PSMA‑positive metastatic castration‑resistant prostate cancer to see if the treatment is safe and shows anti-tumor activity.

  Recruiting Phase 1 Affiliated Hospital of Jiangnan University · Wuxi, Jiangsu · NCT07537010

• Xaluritamig in adults with metastatic castration-resistant prostate cancer

  A new drug called xaluritamig is being tested in adults with metastatic castration-resistant prostate cancer to see if it is safe with the planned dosing.

  Recruiting at 14 sites Phase 1 Amgen · Denver, Colorado and 13 other locations · NCT07493512

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.